Epithelial-to-mesenchymal transition predicts prognosis of pancreatic cancer

Surgery (United States)

Volumn 154, Issue 5, 2013, Pages 946-954

  Yamada, Suguru ^a   Fuchs, Bryan C ^b   Fujii, Tsutomu ^a   Shimoyama, Yoshie ^c   Sugimoto, Hiroyuki ^a   Nomoto, Shuji ^a   Takeda, Shin ^a   Tanabe, Kenneth K ^b   Kodera, Yasuhiro ^a   Nakao, Akimasa ^d  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b HARVARD MEDICAL SCHOOL   (United States)

^c NAGOYA UNIVERSITY HOSPITAL   (Japan)

^d NAGOYA CENTRAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; GEMCITABINE; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR; UVOMORULIN; VIMENTIN; CADHERIN; TUMOR MARKER;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; EPITHELIUM TUMOR; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; LIVER METASTASIS; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MESENCHYME CELL; METASTASIS; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PORTAL VEIN; PRIORITY JOURNAL; STAINING; SURVIVAL RATE; SURVIVAL TIME; METABOLISM; MIDDLE AGED; MORTALITY; PANCREATIC NEOPLASMS; PROGNOSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CADHERINS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; VIMENTIN;

EID: 84886100472     PISSN: 00396060     EISSN: 15327361     Source Type: Journal    
DOI: 10.1016/j.surg.2013.05.004     Document Type: Article

References (35)

1. C.J. Wray, S.A. Ahmad, J.B. Matthews, and A.M. Lowy Surgery for pancreatic cancer: recent controversies and current practice Gastroenterology 128 2005 1626 1641
2. J.L. Cameron, T.S. Riall, J. Coleman, and K.A. Belcher One thousand consecutive pancreaticoduodenectomies Ann. Surg 244 2006 10 15
3. M. Hidalgo Pancreatic cancer N Engl J Med 362 2010 1605 1617
4. Y.Z. Chang, L. Yang, and C.Q. Yang Migration of hepatic stellate cells in fibrotic microenvironment of diseased liver model Hepatobil Pancreat Dis Int 7 2008 401 405
5. R. Kalluri, and R.A. Weinberg The basics of epithelial-mesenchymal transition J Clin Invest 119 2009 1420 1428
6. J.P. Thiery Epithelial-mesenchymal transitions in tumour progression Nat Rev Cancer 2 2002 442 454
7. B. Hotz, M. Arndt, S. Dullat, S. Bhargava, H.J. Buhr, and H.G. Hotz Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer Clin. Cancer Res 13 2007 4769 4776
8. M.M. Javle, J.F. Gibbs, and K.K. Iwata Epithelial-mesenchymal transition (EMT) and activated extracellular signal-regulated kinase (p-Erk) in surgically resected pancreatic cancer Ann Surg Oncol 14 2007 3527 3533
9. S.A. Mani, W. Guo, and M.J. Liao The epithelial-mesenchymal transition generates cells with properties of stem cells Cell 133 2008 704 715
10. G.Z. Cheng, J. Chan, Q. Wang, W. Zhang, C.D. Sun, and L.H. Wang Twist transcriptionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel Cancer Res 67 2007 1979 1987
11. B.C. Fuchs, T. Fujii, and J.D. Dorfman Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells Cancer Res 68 2008 2391 2399
12. T. Arumugam, V. Ramachandran, and K.F. Fournier Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer Cancer Res 69 2009 5820 5828
13. A. Cano, M.A. Perez-Moreno, and I. Rodrigo The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression Nat Cell Biol 2 2000 76 83
14. J. Yang, and R.A. Weinberg Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis Dev Cell 14 2008 818 829
15. H. Kurahara, S. Takao, and K. Maemura Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer J Surg Oncol 105 2012 655 661
16. J. Yang, S.A. Mani, and J.L. Donaher Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis Cell 117 2004 927 939
17. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial- mesenchymal transitions in development and disease Cell 139 2009 871 890
18. C. Pena, J.M. Garcia, and J. Silva E-cadherin and vitamin D receptor regulation by SNAIL and ZEB1 in colon cancer: clinicopathological correlations Hum Mol Genet 14 2005 3361 3370
19. Y. Uchikado, S. Natsugoe, and H. Okumura Slug expression in the E-cadherin preserved tumors is related to prognosis in patients with esophageal squamous cell carcinoma Clin Cancer Res 11 2005 1174 1180
20. E.A. Collisson, A. Sadanandam, and P. Olson Subtypes of pancreatic ductal adenocarcinoma and their differing responses to therapy Nat Med 17 2011 500 503
21. M.H. Yang, D.S. Hsu, and H.W. Wang Bmi1 is essential in Twist1-induced epithelial-mesenchymal transition Nat Cell Biol 12 2010 982 992
22. A.D. Rhim, E.T. Mirek, and N.M. Aiello EMT and dissemination precede pancreatic tumor formation Cell 148 2012 349 361
23. U. Wellner, J. Schubert, and U.C. Burk The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs Nat Cell Biol 11 2009 1487 1495
24. Y. Li, T.G. VandenBoom 2nd, and D. Kong Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells Cancer Res 69 2009 6704 6712
25. C. Gungor, H. Zander, and K.E. Effenberger Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer Cancer Res 71 2011 5009 5019
26. P.P. Bringuier, R. Umbas, H.E. Schaafsma, H.F. Karthaus, F.M. Debruyne, and J.A. Schalken Decreased E-cadherin immunoreactivity correlates with poor survival in patients with bladder tumors Cancer Res 53 1993 3241 3245
27. A. Katagiri, R. Watanabe, and Y. Tomita E-cadherin expression in renal cell cancer and its significance in metastasis and survival Br J Cancer 71 1995 376 379
28. A. Jawhari, S. Jordan, S. Poole, P. Browne, M. Pignatelli, and M.J. Farthing Abnormal immunoreactivity of the E-cadherin-catenin complex in gastric carcinoma: relationship with patient survival Gastroenterology 112 1997 46 54
29. P.J. Richmond, A.J. Karayiannakis, A. Nagafuchi, A.V. Kaisary, and M. Pignatelli Aberrant E-cadherin and alpha-catenin expression in prostate cancer: correlation with patient survival Cancer Res 57 1997 3189 3193
30. S.S. Kantak, and R.H. Kramer E-cadherin regulates anchorage-independent growth and survival in oral squamous cell carcinoma cells J Biol Chem 273 1998 16953 16961
31. K. Endo, T. Ueda, J. Ueyama, T. Ohta, and T. Terada Immunoreactive E-cadherin, alpha-catenin, beta-catenin, and gamma-catenin proteins in hepatocellular carcinoma: relationships with tumor grade, clinicopathologic parameters, and patients' survival Hum Pathol 31 2000 558 565
32. C.E. Gillett, D.W. Miles, and K. Ryder Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast J Pathol 193 2001 433 441
33. T. Shimamura, M. Sakamoto, and Y. Ino Dysadherin overexpression in pancreatic ductal adenocarcinoma reflects tumor aggressiveness: relationship to E-cadherin expression J Clin Oncol 21 2003 659 667
34. S.M. Hong, A. Li, and K. Olino Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas Mod Pathol 24 2011 1237 1247
35. Z. Wang, Y. Li, and D. Kong Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway Cancer Res 69 2009 2400 2407